ArticleAnnals of nuclear medicine2022
18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment.
Article in Annals of nuclear medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- The prognostic value of pretreatment [European radiology · 2025Pooled it
- Predicting the efficacy of iodine-125 seed implantation therapy for metastatic lesions of radioiodine-refractory differentiated thyroid cancer using pre-operative PET/CT parameters: A clinical study.Journal of contemporary brachytherapy · 2026Article
- Use of volumetric analysis to predict pathologic response in esophageal cancer: a single-institution cohort study.Journal of thoracic disease · 2026Article
- Comparative Analysis of F-18 FDG PET-Based Metabolic Parameters in the Differential Diagnosis of Esophageal Squamous Cell Carcinoma and Adenocarcinoma.World journal of nuclear medicine · 2026Article
- Practice of radiation therapy for squamous cell esophageal cancer in Austria - a survey on behalf of the ÖGRO-GIT.Radiation oncology (London, England) · 2026Article
- Development of a predictive model for lymph node metastasis in esophageal cancer usingJournal of gastrointestinal oncology · 2025Article
- Construction of a multimodal esophageal cancer prognostic model with screening of key genes and investigation of their biological functions.Discover oncology · 2025Article
- Maximum standardised uptake value of positron emission tomography as a predictor of oesophageal cancer outcomes.Journal of cardiothoracic surgery · 2024Article
- From pixels to predictions: the scrying power of molecular imaging.European journal of nuclear medicine and molecular imaging · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose[18F] fluorodeoxyglucose positron emission tomography/computed tomography ([18F] FDG-PET/CT) is used for diagnosis, staging, response assessment and prognosis prediction in different tumors, but its role in esophageal cancer is still debated. The aim of this study was to evaluate the role of semiquantitative baseline PET parameters as possible prognostic and predictive factors in a series of esophageal carcinomas treated with combined modalities.
methods43 patients with esophageal carcinoma were treated with chemoradiotherapy (CRT) followed by surgery in 20 cases and underwent pre-treatment 18F-FDG-PET/CT. Semiquantitative PET parameters were evaluated including Standardized Uptake Value (SUVmax e SUVmean), Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) with isocontour of 41 and 50%. Further variables analyzed were gender, primary tumor site, histological type, use of surgery, achievement of a radical resection and the type of chemotherapy regimen. The correlation of all variables with treatment response, loco-regional control (LR), Overall survival (OS) and Disease-Free Survival (DFS) was evaluated.
resultsSUVmax, SUVmean50 and SUVmean41 were significantly higher in node-positive cases and in squamous cell carcinomas. With respect to prognostic factors, MTV was found to be correlated with OS: patients with MTV41 < 11.32 cm
conclusionsPre-treatment MTV values were significant prognostic factors for OS, together with the use of surgery and R0 resection in esophageal cancers treated with multimodal therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.